학술논문
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial
Document Type
Article
Author
Ferrante, M.; Panaccione, R.; Baert, F.; Bossuyt, P.; Colombel, J.-F.; Dubinsky, M.; Danese, S.; Feagan, B.G.; Hisamatsu, T.; Lim, A.; Lindsay, J.O.; Loftus, E.V.; Panés, J.; Peyrin-Biroulet, L.; Ran, Z.; Rubin, D.T.; Sandborn, W.J.; Schreiber, S.; Neimark, E.; Song, A.; Kligys, K.; Pang, Y.; Pivorunas, V.; Berg, S.; Duan, W.R.; Huang, B.; Liao, X.; Robinson, A.; Wallace, K.; Kalabic, J.; D'Haens, G.
Source
In: The Lancet . (The Lancet, 28 May 2022, 399(10340):2031-2046)
Subject
Language
English
ISSN
1474547X
01406736
01406736